Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02563002
Title Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

colorectal cancer

Therapies

Fluorouracil + Leucovorin + Oxaliplatin

Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin

Fluorouracil + Irinotecan + Leucovorin

Cetuximab + Fluorouracil + Irinotecan + Leucovorin

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin

Cetuximab + Fluorouracil + Leucovorin + Oxaliplatin

Pembrolizumab

Age Groups: adult | senior
Covered Countries


No variant requirements are available.